Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems

Journal of Pharmaceutical Sciences

Volumn 98, Issue 3, 2009, Pages 812-843

  Sharma, Sameer ^a   Mukkur, T K S ^a   Benson, Heather A E ^a   Chen, Yan ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Adjuvants; Industrial aspects; Intranasal delivery; Liposomes; Microparticles; Nanoparticles; Particulate systems; Vaccines

Indexed keywords

ALGINIC ACID; BACTERIAL VACCINE; BETA GALACTOSIDASE; CHITOSAN; CHOLERA VACCINE; COCHLEATE; DNA VACCINE; DRUG CARRIER; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLUENZA VACCINE; ISCOM; LIPOSOME; MENINGOCOCCUS VACCINE; NANOPARTICLE; NIOSOME; PEPTIDE VACCINE; PERTUSSIS VACCINE; POLYLACTIC ACID; PROTEOSOME; QUIL A; RADIOISOTOPE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; SHIGELLA VACCINE; TETANUS TOXOID; TETANUS TOXOID I 125; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIROSOME;

ANTIGEN PRESENTING CELL; BELL PALSY; CELLULAR IMMUNITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; INTERMETHOD COMPARISON; LYMPHOID TISSUE; MICROENCAPSULATION; MUCOSAL IMMUNITY; NANOENCAPSULATION; NONHUMAN; NOSE MUCOSA; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN INTERACTION; PROTEOLIPOSOME; RESPIRATORY TRACT INFECTION; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS LIKE AGENT;

EID: 62849109927     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21493     Document Type: Review

References (249)

1. Jiskoot W, Kersten GFA, Beuvery EC. 2002. Vaccines. In: Crommelin DJA, Sindelar RD, editors. Pharmaceutical biotechnology, 2nd edition. London: Taylor & Francis. pp. 259-281.
2. Bramwell VW, Perrie Y. 2005. The rational design of vaccines. Drug Discov Today 10:1527-1534.
3. Yuki Y, Nochi T, Kiyono H. 2007. Progress towards an AIDS mucosal vaccine: An overview. Tuberculosis 87:S35-S44.
4. Moingeon P, Haensler J, Lindberg A. 2001. Towards the rational design of Th1 adjuvants. Vaccine 19:4363-4372.
5. Men Y, Gander B, Merkle HP, Corradin G. 1996. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres. Vaccine 14:1442-1450.
6. Mestecky J, Michalek SM, Moldoveanu Z, Russell MW. 1997. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans. Behring Inst Mitt 98:33-43.
7. Manocha M, Pal PC, Chitralekha KT, Thomas BE, Tripathi V, Gupta SD, Paranjape R, Kulkarni S, Rao DN. 2005. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 23:5599-5617.
8. Reddy ST, Swartz MA, Hubbell JA. 2006. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol 27:573-579.
9. Reddy ST, van der Vlies AJ, Simeoni E, Angeli V, Randolph GJ, O'Neil CP, Lee LK, Swartz MA, Hubbell JA. 2007. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol 25:1159-1164.
10. Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, Russell MW. 1997. Current options for vaccine delivery systems by mucosal routes. J Control Release 48:243-257.
11. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol 6:148-158.
12. Mestecky J, Lue C, Russell MW. 1991. Selective transport of IgA. Cellular and molecular aspects. Gastroenterol Clin North Am 20:441-471.
13. Brandtzaeg P, Pabst R. 2004. Let's go mucosal: Communication on slippery ground. Trends Immunol 25:570-577.
14. Brandtzaeg P. 2007. Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann NY Acad Sci 1098:288-311.
15. Brandtzaeg P. 2007. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467-5484.
16. Brandtzaeg P, Farstad IN, Haraldsen G. 1999. Regional specialization in the mucosal immune system: Primed cells do not always home along the same track. Immunol Today 20:267-277.
17. Langman JM, Rowland R. 1986. The number and distribution of lymphoid follicles in the human large intestine. J Anat 149:189-194.
18. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. 1992. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10:75-88.
19. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret J-F. 2003. Experience with registered mucosal vaccines. Vaccine 21:678-683.
20. Mukkur TKS, Walker KH, Baker P, Jones D. 1995. Systemic and mucosal intestinal antibody response of sheep immunized with aromatic-dependent live or killed Salmonella typhimurium. Comp Immunol Microbiol Infect Dis 18:27-39.
21. Kiyono H, Fukuyama S. 2004. NALT- versus PEYER'S-patch-mediated mucosal immunity. Nat Rev Immunol 4:699-710.
22. van Kempen MJ, Rijkers GT, Van Cauwenberge PB. 2000. The immune response in adenoids and tonsils. Int Arch Allergy Immunol 122:8-19.
23. Illum L. 2007. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J Pharm Sci 96:473-483.
24. Fujimura Y, Takeda M, Ikai H, Haruma K, Akisada T, Harada T, Sakai T, Ohuchi M. 2004. The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch 444:36-42.
25. Perry M, Whyte A. 1998. Immunology of the tonsils. Immunol Today 19:414-421.
26. Gebert A, Pabst R. 1999. M cells at locations outside the gut. Semin Immunol 11:165-170.
27. Davis SS. 2001. Nasal vaccines. Adv Drug Del Rev 51:21-42.
28. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. 2007. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis 87:257-266.
29. Brandtzaeg P, Pabst R. 2004. Let's go mucosal: Communication on slippery ground. Trends Immunol 25:570-577.
30. Yamanaka T, Helgeland L, Farstad IN, Fukushima H, Midtvedt T, Brandtzaeg P. 2003. Microbial colonization drives lymphocyte accumulation and differentiation in the follicle-associated epithelium of Peyer's patches. J Immunol 170:816-822.
31. Brandtzaeg P. 2007. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 25:5467-5484.
32. Neutra MR, Pringault E, Kraehenbuhl JP. 1996. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu Rev Immunol 14:275-300.
33. Slutter B, Hagenaars N, Jiskoot W. 2008. Rational design of nasal vaccines. J Drug Target 16:1-17.
34. Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen F-E, Nilsen EM, Yamanaka T. 1999. Regional specialization in the mucosal immune system: What happens in the microcompartments? Immunol Today 20:141-151.
35. O'Hagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727-735.
36. Vajdy M, O'Hagan DT. 2001. Microparticles for intranasal immunization. Adv Drug Del Rev 51:127-141.
37. McGhee JR, Lamm ME, Strober W. 1999. Mucosal immune responses: An overview. In: Ogra PL, Lamm ME, Bienenstock J, Mestecky J, Strober W, McGhee JR, editors. Mucosal immunology, 2nd edition. San Diego: Academic Press. pp. 485-506.
38. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat Med 11:S45-S53.
39. De Magistris MT. 2006. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Del Rev 58:52-67.
40. Singh M, Briones M, O'Hagan DT. 2001. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release 70:267-276.
41. Fujimura Y, Akisada T, Harada T, Haruma K. 2006. Uptake of microparticles into the epithelium of human nasopharyngeal lymphoid tissue. Med Mol Morphol 39:181-186.
42. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350:896-903.
43. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. 2006. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release 116:1-27.
44. Singh M, Chakrapani A, O'Hagan D. 2007. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 6:797-808.
45. Singh M, O'Hagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res 19:715-728.
46. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. 1993. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451.
47. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kundig T, Bachi T, Storni T, Jennings G, Pumpens P, Renner WA, Bachmann MF. 2002. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20:3104-3112.
48. Kraehenbuhl JP, Neutra MR. 2000. Epithelial M cells: Differentiation and function. Annu Rev Cell Dev Biol 16:301-332.
49. Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, Neutra MR. 1996. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting. J Exp Med 184:1045-1059.
50. Owen RL. 1977. Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: An ultrastructural study. Gastroenterol 72:440-451.
51. Neutra MR, Giannasca PJ, Troidle K, Kraehenbuhl JP. 1995. M cells and microbial pathogens. In: Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant L, editors. Infections of the gastrointestinal tract, 1st edition. New York: Raven. pp. 163-178.
52. Jones BD, Ghori N, Falkow S. 1994. Salmonella typhimurium initiates murine infection by penetrating and destroying the specialized epithelial M cells of the Peyer's patches. J Exp Med 180:15-23.
53. Kallenius G, Pawlowski A, Brandtzaeg P, Svenson S. 2007. Should a new tuberculosis vaccine be administered intranasally? Tuberculosis 87:257-266.
54. Brooking J, Davis SS, Illum L. 2001. Transport of nanoparticles across the rat nasal mucosa. J Drug Target 9:267-279.
55. Eyles JE, Carpenter ZC, Alpar HO, Williamson ED. 2003. Immunological aspects of polymer microsphere vaccine delivery systems. J Drug Target 11:509-514.
56. Locht C, Antoine R, Raze D, Mielcarek N, Hot D, Lemoine Y, Mascart F. 2004. Bordetella pertussis from functional genomics to intranasal vaccination. Int J Med Microbiol 293:583-588.
57. Carcaboso AM, Hernandez RM, Igartua M, Rosas JE, Patarroyo ME, Pedraz JL. 2004. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22:1423-1432.
58. Tobio M, Gref R, Sanchez A, Langer R, Alonso MJ. 1998. Stealth PLA-PEG nanoparticles as protein carriers for nasal administration. Pharm Res 15:270-275.
59. Vila A, Sanchez A, Evora C, Soriano I, McCallion O, Alonso MJ. 2005. PLA-PEG particles as nasal protein carriers: The influence of the particle size. Int J Pharm 292:43-52.
60. Vila A, Sanchez A, Tobio M, Calvo P, Alonso MJ. 2002. Design of biodegradable particles for protein delivery. J Control Release 78:15-24.
61. Schwendeman SP. 2002. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 19:73-98.
62. Jones DH, Corris S, McDonald S, Clegg JCS, Farrar GH. 1997. Poly(-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 15:814-817.
63. Eyles JE, Bramwell VW, Williamson ED, Alpar HO. 2001. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19:4732-4742.
64. Jaganathan KS, Singh P, Prabakaran D, Mishra V, Vyas SP. 2004. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B. J Pharm Pharmacol 56:1243-1250.
65. Eyles JE, Williamson ED, Alpar HO. 1999. Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume. Int J Pharm 189:75-79.
66. Men Y, Tamber H, Audran R, Gander B, Corradin G. 1997. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine 15:1405-1412.
67. Storni T, Kundig TM, Senti G, Johansen P. 2005. Immunity in response to particulate antigendelivery systems. Adv Drug Del Rev 57:333-355.
68. Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O'Hagan DT, Mills KH. 1995. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIVspecific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine 13:1741-1749.
69. Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M. 2004. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines. Immunol Cell Biol 82:617-627.
70. Ruedl C, Bachmann MF, Kopf M. 2000. The antigen dose determines T helper subset development by regulation of CD40 ligand. Eur J Immunol 30:2056-2064.
71. Coombes AG, Major D, Wood JM, Hockley DJ, Minor PD, Davis SS. 1998. Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines. Biomaterials 19:1073-1081.
72. Jabbal-Gill I, Lin W, Kistner O, Davis SS, Illum L. 2001. Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Del Rev 51:97-111.
73. Bramwell VW, Perrie Y. 2006. Particulate delivery systems for vaccines: What can we expect? J Pharm Pharmacol 58:717-728.
74. Baras B, Benoit MA, Dupre L, Poulain-Godefroy O, Schacht AM, Capron A, Gillard J, Riveau G. 1999. Single-dose mucosal immunization with biodegradable microparticles containing a Schistosoma mansoni antigen. Infect Immun 67:2643-2648.
75. Higaki M, Takase T, Igarashi R, Suzuki Y, Aizawa C, Mizushima Y. 1998. Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin. Vaccine 16:741-745.
76. Andrianov AK, Chen J, Payne LG. 1998. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 19:109-115.
77. Payne LG, Andrianov AK. 1998. Protein release from polyphosphazene matrices. Adv Drug Del Rev 31:185-196.
78. Voltan R, Castaldello A, Brocca-Cofano E, Altavilla G, Caputo A, Laus M, Sparnacci K, Ensoli B, Spaccasassi S, Ballestri M, Tondelli L. 2007. Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes. Pharm Res 24:1870-1882.
79. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. 1999. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55-65.
80. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51:81-96.
81. Illum L. 1998. Chitosan and its use as a pharmaceutical excipient. Pharm Res 15:1326-1331.
82. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan and its derivatives in mucosal drug and vaccine delivery. Euro J Pharm Sci 14:201-207.
83. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan for mucosal vaccination. Adv Drug Del Rev 52:139-144.
84. Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJA, Jiskoot W. 2007. N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model. Vaccine 25:144-153.
85. Soane RJ, Hinchcliffe M, Davis SS, Illum L. 2001. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int J Pharm 217:183-191.
86. Sharma S, Kulkarni J, Pawar AP. 2006. Permeation enhancers in the transmucosal delivery of macromolecules. Pharmazie 61:495-504.
87. Vila A, Sanchez A, Janes K, Behrens I, Kissel T, Jato JLV, Alonso MJ. 2004. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Euro J Pharm Biopharm 57:123-131.
88. Issa MM, Koping-Hoggard M, Tommeraas K, Varum KM, Christensen BE, Strand SP, Artursson P. 2006. Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo. J Control Release 115:103-112.
89. Chen Y, Mohanraj V, Parkin J. 2003. Chitosan-dextran sulfate nanoparticles for delivery of an anti-angiogenesis peptide. Int J Pept Res Ther 10:621-629.
90. Rebelatto MC, Guimond P, Bowersock TL, Hogen-Esch H. 2001. Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Vet Immunol Immunopathol 83:93-105.
91. Tafaghodi M, Sajadi Tabassi SA, Jaafari MR. 2006. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 319:37-43.
92. Heritage PL, Brook MA, Underdown BJ, McDermott MR. 1998. Intranasal immunization with polymer-grafted microparticles activates the nasal-associated lymphoid tissue and draining lymph nodes. Immunology 93:249-256.
93. McDermott MR, Heritage PL, Bartzoka V, Brook MA. 1998. Polymer-grafted starch microparticles for oral and nasal immunization. Immunol Cell Biol 76:256-262.
94. Illum L, Farraj NF, Fisher AN, Gill I, Miglietta M, Benedetti LM. 1994. Hyaluronic acid ester microspheres as a nasal delivery system for insulin. J Control Release 29:133-141.
95. Richardson JL, Ramires PA, Miglietta MR, Rochira M, Bacelle L, Callegaro L, Benedetti L. 1995. Novel vaginal delivery systems for calcitonin: I. Evaluation of HYAFF/calcitonin microspheres in rats. Int J Pharm 115:9-15.
96. Pouyani T, Prestwich GD. 1994. Functionalized derivatives of hyaluronic acid oligosaccharides: Drug carriers and novel biomaterials. Bioconjug Chem 5:339-347.
97. Benedetti LM, Topp EM, Stella VJ. 1990. Microspheres of hyaluronic acid esters - Fabrication methods and in vitro hydrocortisone release. J Control Release 13:33-41.
98. Hume LR, Lee HK, Benedetti L, Sanzgiri YD, Topp EM, Stella VJ. 1994. Ocular sustained delivery of prednisolone using hyaluronic acid benzyl ester films. Int J Pharm 111:295-298.
99. Campoccia D, Doherty P, Radice M, Brun P, Abatangelo G, Williams DF. 1998. Semisynthetic resorbable materials from hyaluronan esterification. Biomaterials 19:2101-2127.
100. Sesardic D. 2006. Regulatory considerations on new adjuvants and delivery systems. Vaccine 24:S86-S87.
101. Copland MJ, Rades T, Davies NM, Baird MA. 2005. Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 83:97-105.
102. Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA. 2000. Vaccine delivery: Lipid-based delivery systems. J Biotech 83:91-104.
103. Kersten GFA, Crommelin DJA. 1995. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta Rev Biomemb 1241:117-138.
104. Fortin A, Therien HM. 1993. Mechanism of liposome adjuvanticity: An in vivo approach. Immunobiology 188:316-322.
105. Liang MT, Davies NM, Blanchfield JT, Toth I. 2006. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr Drug Deliv 3:379-388.
106. Alpar HO, Bowen JC, Brown MRW. 1992. Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid. Int J Pharm 88:335-344.
107. Tafaghodi M, Jaafari MR, Sajadi Tabassi SA. 2006. Nasal immunization studies using liposomes loaded with tetanus toxoid and CpGODN. Eur J Pharm Biopharm 64:138-145.
108. Aramaki Y, Fujii Y, Yachi K, Kikuchi H, Tsuchiya S. 1994. Activation of systemic and mucosal immune response following nasal administration of liposomes. Vaccine 12:1241-1245.
109. Brownlie RM, Brahmbhatt HN, White DC, Fountain MW, Rohde M, Wehland J, Timmis KN. 1993. Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome-incorporated cell-surface antigens. Microb Pathog 14:149-160.
110. Perry RD, Fetherston JD. 1997. Yersinia pestis - Etiologic agent of plague. Clin Microbiol Rev 10:35-66.
111. Gupta RK, Siber GR. 1995. Adjuvants for human vaccines - Current status, problems and future prospects. Vaccine 13:1263-1276.
112. Bomford R, Stapleton M, Winsor S, Beesley JE, Jessup EA, Price KR, Fenwick GR. 1992. Adjuvanticity and ISCOM formation by structurally diverse saponins. Vaccine 10:572-577.
113. Kersten GF, Spiekstra A, Beuvery EC, Crommelin DJ. 1991. On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta 1062:165-171.
114. Kersten GF, Teerlink T, Derks HJ, Verkleij AJ, van Wezel TL, Crommelin DJ, Beuvery EC. 1988. Incorporation of the major outer membrane protein of Neisseria gonorrhoeae in saponin-lipid complexes (iscoms): Chemical analysis, some structural features, and comparison of their immunogenicity with three other antigen delivery systems. Infect Immun 56:432-438.
115. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. 1984. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308:457-460.
116. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, Sutton P, Rockman S, Pearse M. 2003. Intranasal vaccination with ISCOMATRIX(R) adjuvanted influenza vaccine. Vaccine 21:946-949.
117. Morein B, Villacres-Eriksson M, Ekstrom J, Hu K, Behboudi S, Lovgren-Bengtsson K. 1999. ISCOM: A delivery system for neonates and for mucosal administration. Adv Vet Med 41:405-413.
118. Trudel M, Nadon F, Seguin C, Brault S, Lusignan Y, Lemieux S. 1992. Initiation of cytotoxic T-cell response and protection of Balb/c mice by vaccination with an experimental ISCOMs respiratory syncytial virus subunit vaccine. Vaccine 10:107-112.
119. Hu KF, Elvander M, Merza M, Akerblom L, Brandenburg A, Morein B. 1998. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol 113:235-243.
120. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, Steinman RM. 2000. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 151:673-684.
121. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, Nussenzweig MC. 1995. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375:151-155.
122. Morein B, Ekstrom J, Lovgren K. 1990. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J Immunol Methods 128:177-181.
123. Reid G. 1992. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine 10:597-602.
124. Scheerlinck J-PY, Gekas S, Yen H-H, Edwards S, Pearse M, Coulter A, Sutton P. 2006. Local immune responses following nasal delivery of an adjuvanted influenza vaccine. Vaccine 24:3929-3936.
125. Hu K-F, Lovgren-Bengtsson K, Morein B. 2001. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Del Rev 51:149-159.
126. Scholl I, Boltz-Nitulescu G, Jensen-Jarolim E. 2005. Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy. J Control Release 104:1-27.
127. Gluck R. 1992. Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens. Vaccine 10:915-919.
128. Gluck R. 1999. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine 17:1782-1787.
129. Gluck R, Metcalfe IC. 2002. New technology platforms in the development of vaccines for the future. Vaccine 20:B10-B16.
130. Cusi MG, Terrosi C, Savellini GG, Genova GD, Zurbriggen R, Correale P. 2004. Efficient delivery of DNA to dendritic cells mediated by influenza virosomes. Vaccine 22:736-740.
131. Bungener L, Serre K, Bijl L, Leserman L, Wilschut J, Daemen T, Machy P. 2002. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine 20:2287-2295.
132. Perez O, Bracho G, Lastre M, Mora N, del Campo J, Gil D, Zayas C, Acevedo R, Gonzalez D, Lopez JA, Taboada C, Turtle C, Solis RL. 2004. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunol Cell Biol 82:603-610.
133. El Guink N, Kris RM, Goodman-Snitkoff G, Small PA, Mannino RJ. 1989. Intranasal immunization with proteoliposomes protects against influenza. Vaccine 7:147-151.
134. Gould-Fogerite S, Kheiri MT, Zhang F, Wang Z, Scolpino AJ, Feketeova E, Canki M, Mannino RJ. 1998. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Del Rev 32:273-287.
135. Gould-Fogerite S, Mannino RJ. 1996. Mucosal and systemic immunization using cochleate and liposome vaccines. J Liposome Res 6:357-379.
136. Mannino RJ, Gould-Fogerite S. 1995. Lipid matrix-based vaccines for mucosal and systemic immunization. In: Powell MF, Newman MJ, Burdman JR, editors. Vaccine design: The subunit and adjuvant approach, 1st edition. New York: Plenum Press. pp. 363-387.
137. Mannino RJ, Canki M, Feketeova E, Scolpino AJ, Wang Z, Zhang F, Kheiri MT, Gould-Fogerite S. 1998. Targeting immune response induction with cochleate and liposome-based vaccines. Adv Drug Del Rev 32:273-287.
138. Michalek SM, O'Hagan DT, Childers NK, Osterhaus ADME, Rimmelzwaan GF. 2005. Antigen delivery systems I: Nonliving microparticles, liposomes, and immune stimulating complexes (ISCOMs). In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Mucosal immunology, 3rd edition. San Diego: Academic Press. pp. 987-1007.
139. Chen X, Doffek K, Sugg SL, Shilyansky J. 2004. Phosphatidylserine regulates the maturation of human dendritic cells. J Immunol 173:2985-2994.
140. Hoffmann PR, Kench JA, Vondracek A, Kruk E, Daleke DL, Jordan M, Marrack P, Henson PM, Fadok VA. 2005. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J Immunol 174:1393-1404.
141. Zarif L, Mannino R. 2000. Cochleates: Lipid based vehicles for gene delivery-concept, achievements and future development. In: Habib N, editor. Cancer gene therapy: Past achievements and future challenges, 1st edition. New York: Kleuwer Academic/Plenum Press. pp. 83-93.
142. del Campo J, Lastre M, Bracho G, Rodriguez T, Gil D, Zayas C, Taboada C, Acevedo R, Perez DR, Perez O. 2006. Immunological evaluation of bacterial derived Cochleate and Proteoliposome as mucosal adjuvants. Vaccine 24:S50-S51.
143. Perez O, Bracho G, Lastre M, Zayas C, Gonzalez D, Gil D, del Campo J, Acevedo R, Taboada C, Rodriguez T, Fajardo ME, Sierra G, Campa C, Mora N, Barbera R, Solis RL. 2006. Proteliposome-derived Cochleate as an immunomodulator for nasal vaccine. Vaccine 24:S52-S53.
144. Zayas C, Bracho G, Lastre M, Gonzalez D, Gil D, Acevedo R, del Campo J, Taboada C, Solis RL, Barbera R, Perez O. 2006. Scale up of proteoliposome derived Cochleate production. Vaccine 24:S94-S95.
145. Gil D, Bracho G, Zayas C, del Campo J, Acevedo R, Toledo A, Lastre M, Perez O. 2006. Strategy for determination of an efficient Cochleate particle size. Vaccine 24:S92-S93.
146. Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, Arnon R. 1995. Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 13:1353-1359.
147. Frasch CE, Peppler MS. 1982. Protection against group B Neisseria meningitidis disease: Preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun 37:271-280.
148. Orr N, Robin G, Cohen D, Arnon R, Lowell GH. 1993. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun 61:2390-2395.
149. Jones T, Allard F, Cyr SL, Tran SP, Plante M, Gauthier J, Bellerose N, Lowell GH, Burt DS. 2003. A nasal Proteosome(TM) influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21:3706-3712.
150. Treanor J, Nolan C, O'Brien D, Burt D, Lowell G, Linden J, Fries L. 2006. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 24:254-262.
151. Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. 2001. Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect Immun 69:4545-4553.
152. Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis-Price L, Smith G, Redfield RR, Amselem S, Birx DL. 1997. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 175:292-301.
153. VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL. 1998. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160:2000-2012.
154. von Hoegen P. 2001. Synthetic biomimetic supra molecular Biovector(TM) (SMBV(TM)) particles for nasal vaccine delivery. Adv Drug Del Rev 51:113-125.
155. Debin A, Kravtzoff R, Santiago JV, Cazales L, Sperandio S, Melber K, Janowicz Z, Betbeder D, Moynier M. 2002. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine 20:2752-2763.
156. Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M. 2005. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults. Human Vaccines 1:37-42.
157. Kravtzoff R, Fisher A, De Miguel I, Perkins A, Major M, Betbeder D. 1998. Proceedings of the International Symposium on Controlled Release of Bioactive Materials, pp. 818-819.
158. Chattaraj SC, Das SK. 2003. Physicochemical characterization of influenza viral vaccine loaded surfactant vesicles. Drug Deliv 10:73-77.
159. Yoshioka T, Skalko N, Gursel M, Gregoriadis G, Florence AT. 1995. A non-ionic surfactant vesiclein-water-in-oil (v/w/o) system: Potential uses in drug and vaccine delivery. J Drug Target 2:533-539.
160. Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM. 2007. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine 25:5968-5977.
161. Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. 2001. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J Virol 75:9713-9722.
162. Eriksson K, Holmgren J. 2002. Recent advances in mucosal vaccines and adjuvants. Current Opinion Immunol 14:666-672.
163. Nagamoto T, Hattori Y, Takayama K, Maitani Y. 2004. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res 21:671-674.
164. Koping-Hoggard M, Sanchez A, Alonso MJ. 2005. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev Vaccines 4:185-196.
165. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. 2006. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40:1-9.
166. Jung J, Perrut M. 2001. Particle design using supercritical fluids: Literature and patent survey. J Supercrit Fluids 20:179-219.
167. Alpar HO, Eyles JE, Williamson ED, Somavarapu S. 2001. Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Del Rev 51:173-201.
168. Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. 2002. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 21:67-77.
169. Singh J, Pandit S, Bramwell VW, Alpar HO. 2006. Diphtheria toxoid loaded poly-([epsilon]-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods 38:96-105.
170. Alpar HO, Almeida AJ. 1994. Identification of some of the physico-chemical characteristics of microspheres which influence the induction of the immune response following mucosal delivery. Euro J Pharm Biopharm 40:198-202.
171. Vila A, Gill H, McCallion O, Alonso MJ. 2004. Transport of PLA-PEG particles across the nasal mucosa: Effect of particle size and PEG coating density. J Control Release 98:231-244.
172. Jani P, Halbert GW, Langridge J, Florence AT. 1990. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol 42:821-826.
173. Li Wan Po A, Rogers E, Shepphard M, Scott EM. 1995. Delivery systems for non-parenteral vaccines. Adv Drug Del Rev 18:101-109.
174. des Rieux A, Fievez V, Théate I, Mast J, Préat V, Schneider Y-J. 2007. An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Euro J Pharm Sci 30:380-391.
175. Rieux Ad, Ragnarsson EGE, Gullberg E, Préat V, Schneider Y-J, Artursson P. 2005. Transport of nanoparticles across an in vitro model of the human intestinal follicle associated epithelium. Euro J Pharm Sci 25:455-465.
176. Baeyens V, Gurny R. 1997. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm Acta Helv 72:191-202.
177. Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E. 2006. A new intranasal influenza
178. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Del Rev 57:411-430.
179. Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG. 2003. Preparation and purification of cationic solid lipid nanospheres - Effects on particle size, physical stability and cell toxicity. Int J Pharm 254:83-87.
180. Jaganathan KS, Vyas SP. 2006. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant Hepatitis B antigen administered intranasally. Vaccine 24:4201-4211.
181. MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, Rolland AP. 1998. Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 56:259-272.
182. Singh M, Briones M, Ott G, O'Hagan D. 2000. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci USA 97:811-816.
183. Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. 2004. Intranasal delivery of chitosan-DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine 22:3603-3612.
184. Vajdy M, Singh M, Kazzaz J, Soenawan E, Ugozzoli M, Zhou F, Srivastava I, Bin Q, Barnett S, Donnelly J, Luciw P, Adamson L, Montefiori D, O'Hagan DT. 2004. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. AIDS Res Hum Retroviruses 20:1269-1281.
185. Kim TW, Chung H, Kwon IC, Sung HC, Kang TH, Han HD, Jeong SY. 2006. Induction of immunity against hepatitis B virus surface antigen by intranasal DNA vaccination using a cationic emulsion as a mucosal gene carrier. Mol Cells 22:175-181.
186. Hyde SC, Southern KW, Gileadi U, Fitzjohn EM, Mofford KA, Waddell BE, Gooi HC, Goddard CA, Hannavy K, Smyth SE, Egan JJ, Sorgi FL, Huang L, Cuthbert AW, Evans MJ, Colledge WH, Higgins CF, Webb AK, Gill DR. 2000. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 7:1156-1165.
187. Romoren K, Thu BJ, Bols NC, Evensen O. 2004. Transfection efficiency and cytotoxicity of cationic liposomes in salmonid cell lines of hepatocyte and macrophage origin. Biochim Biophys Acta Biomembr 1663:127-134.
188. Tiyaboonchai W, Woiszwillo J, Middaugh CR. 2003. Formulation and characterization of DNA-polyethylenimine-dextran sulfate nanoparticles. Eur J Pharm Sci 19:191-202.
189. Akagi T, Wang X, Uto T, Baba M, Akashi M. 2007. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28:3427-3436.
190. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. 2005. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Del Rev 57:411-430.
191. Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. 2008. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 26:2225-2233.
192. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. 2006. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system. J Control Release 111:107-116.
193. Spiers ID, Eyles JE, Baillie LW, Williamson ED, Alpar HO. 2000. Biodegradable microparticles with different release profiles: Effect on the immune response after a single administration via intranasal and intramuscular routes. J Pharm Pharmacol 52:1195-1201.
194. Jelley-Gibbs DM, Lepak NM, Yen M, Swain SL. 2000. Two distinct stages in the transition from naive CD4 T cells to effectors, early antigen-dependent and late cytokine-driven expansion and differentiation. J Immunol 165:5017-5026.
195. Eyles JE, Spiers ID, Williamson ED, Alpar HO. 1998. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere coencapsulated Yersinia pestis sub-unit vaccines. Vaccine 16:2000-2009.
196. Eyles JE, Sharp GJ, Williamson ED, Spiers ID, Alpar HO. 1998. Intra nasal administration of poly-lactic acid microsphere co-encapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine 16:698-707.
197. Elvin SJ, Eyles JE, Howard KA, Ravichandran E, Somavarappu S, Alpar HO, Williamson ED. 2006. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 24:4433-4439.
198. Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J, Langer R, Putnam D. 2004. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 3:190-196.
199. Wang F. 2004. Micro and nanoparticles for sitespecific drug delivery in the skin [M. Pharm thesis]. Perth: Curtin University of Technology.
200. Mellman I, Steinman RM. 2001. Dendritic cells: Specialized and regulated antigen processing machines. Cell 106:255-258.
201. Nguyen DN, Raghavan SS, Tashima LM, Lin EC, Fredette SJ, Langer RS, Wang C. 2008. Enhancement of poly(orthoester) microspheres for DNA vaccine delivery by blending with poly(ethylenimine). Biomaterials 29:2783-2793.
202. Ryan M, McCarthy L, Rappuoli R, Mahon BP, Mills KH. 1998. Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: Adjuvant action is associated with enhanced regulatory cytokine production and expression of the costimulatory molecules B7-1, B7-2 and CD28. Int Immunol 10:651-662.
203. Glueck R. 2001. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 20:S42-S44.
204. Durrer P, Gluck U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Gluck R. 2003. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21:4328-4334.
205. Couch RB. 2004. Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy. N Engl J Med 350:860-861.
206. Ryan EJ, McNeela E, Murphy GA, Stewart H, O'Hagan D, Pizza M, Rappuoli R, Mills KH. 1999. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells. Infect Immun 67:6270-6280.
207. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, Dougan G, Mills KHG, Rappuoli R, Del Giudice G. 2001. Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
208. Peppoloni S, Ruggiero P, Contorni M, Morandi M, Pizza M, Rappuoli R, Podda A, Del Giudice G. 2003. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev Vaccines 2:285-293.
209. Cox E, Verdonck F, Vanrompay D, Goddeeris B. 2006. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet Res 37:511-539.
210. Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG. 2006. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 80:4962-4970.
211. Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. 2003. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 21:3837-3844.
212. Villinger F, Miller R, Mori K, Mayne AE, Bostik P, Sundstrom JB, Sugimoto C, Ansari AA. 2004. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 22:3510-3521.
213. Staats HF, Bradney CP, Gwinn WM, Jackson SS, Sempowski GD, Liao HX, Letvin NL, Haynes BF. 2001. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J Immunol 167:5386-5394.
214. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. 2001. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol 21:103-120.
215. Haile M, Hamasur B, Jaxmar T, Gavier-Widen D, Chambers MA, Sanchez B, Schroder U, Kallenius G, Svenson SB, Pawlowski A. 2005. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice. Tuberculosis 85:107-114.
216. Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT, Michalek SM. 2000. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun 68:5509-5516.
217. Klinman DM. 2003. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2:305-315.
218. Salkowski CA, Detore GR, Vogel SN. 1997. Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun 65:3239-3247.
219. El mir S, Casanova A, Betbeder D, Triebel F. 2001. A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration. Eur J Cancer 37:1053-1060.
220. Baca-Estrada ME, Foldvari M, Snider M. 1999. Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. J Interfer Cytokine Res 19:455-462.
221. Bracci L, Canini I, Puzelli S, Sestili P, Venditti M, Spada M, Donatelli I, Belardelli F, Proietti E. 2005. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23:2994-3004.
222. Staats HF, Ennis FA Jr. 1999. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol 162:6141-6147.
223. Kwon YM, Baudys M, Knutson K, Kim SW. 2001. In situ study of insulin aggregation induced by water-organic solvent interface. Pharm Res 18:1754-1759.
224. Bilati U, Allemann E, Doelker E. 2005. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Euro J Pharm Biopharm 59:375-388.
225. Zhu G, Mallery SR, Schwendeman SP. 2000. Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide). Nat Biotechnol 18:52-57.
226. Johnson OL, Jaworowicz W, Cleland JL, Bailey L, Charnis M, Duenas E, Wu C, Shepard D, Magil S, Last T, Jones AJ, Putney SD. 1997. The stabilization and encapsulation of human growth hormone into biodegradable microspheres. Pharm Res 14:730-735.
227. Standley SM, Kwon YJ, Murthy N, Kunisawa J, Shastri N, Guillaudeu SJ, Lau L, Frechet JM. 2004. Acid-degradable particles for protein-based vaccines: Enhanced survival rate for tumor-challenged mice using ovalbumin model. Bioconjug Chem 15:1281-1288.
228. Roth A, Espuelas S, Thumann C, Frisch B, Schuber F. 2004. Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes. Bioconjug Chem 15:541-553.
229. Jiang H-L, Kang ML, Quan J-S, Kang SG, Akaike T, Yoo HS, Cho C-S. 2008. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials 29:1931-1939.
230. Baca-Estrada ME, Foldvari M, Snider M, Harding K, Kournikakis B, Babiuk LA, Griebel P. 2000. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 18:2203-2211.
231. Djupesland PG, Skretting A, Winderen M, Holand T. 2004. Bi-directional nasal delivery of aerosols can prevent lung deposition. J Aerosol Med 17:249-259.
232. ADIS R&D profile. 2003. Influenza virus vaccine live intranasal - MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R&D 4:312-319.
233. Gluck R. 2002. Intranasal immunization against influenza. J Aerosol Med 15:221-228.
234. Bakke H, Samdal HH, Holst J, Oftung F, Haugen IL, Kristoffersen AC, Haugan A, Janakova L, Korsvold GE, Krogh G, Andersen EA, Djupesland P, Holand T, Rappuoli R, Haneberg B. 2006. Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scand J Imunol 63:223-231.
235. Djupesland PG, Skretting A, Winderen M, Holand T. 2006. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngo 116:466-472.
236. Kresse H. 2007. Medimmune: Flumist sales to heat up. Buisness Review Ltd. www.pharmaceutical-buisnessreview.com/article-feature-print.asp? guid=F62A1684-B18F-4287-95E9-2985BB717995 [accessed February 22, 2008].
237. Glezen WP. 2006. A response to strategy #2: Streamlining the regulatory process. Clin Infect Dis 42:S141-S144.
238. Reid RH, Boedeker EC, McQueen CE, Davis D, Tseng LY, Kodak J, Sau K, Wilhelmsen CL, Nellore R, Dalal P, et al. 1993. Preclinical evaluation of microencapsulated CFA/II oral vaccine against enterotoxigenic E. coli. Vaccine 11:159-167.
239. Hanes J, Chiba M, Langer R. 1995. Polymer microspheres for vaccine delivery. In: Powell MF, Newman MJ, Burdman JR, editors. Vaccine design: The subunit and adjuvant approach. 1st edition. New York: Plenum Press. pp. 389-412.
240. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 57:391-410.
241. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH. 1991. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J Infect Dis 163:1-6.
242. McGhee JR, Mestecky J. 1990. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am 4:315-341.
243. Mestecky J, McGhee JR. 1992. Prospects for human mucosal vaccines. Adv Exp Med Biol 327:13-23.
244. Brandtzaeg P. 1989. Overview of the mucosal immune system. Curr Top Microbiol Immunol 146:13-25.
245. McGhee JR, Czerkinsky C, Mestecky J. 1999. Mucosal vaccines: An overview. In: Ogra PL, Lamm ME, Bienenstock J, Mestecky J, Strober W, McGhee JR, editors. Mucosal immunology, 2nd edition. San Diego: Academic Press. pp. 741-757.
246. Csaba N, Sanchez A, Alonso MJ. 2006. PLGA: poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery. J Control Release 113:164-172.
247. Sakaue G, Hiroi T, Nakagawa Y, Someya K, Iwatani K, Sawa Y, Takahashi H, Honda M, Kunisawa J, Kiyono H. 2003. HIV mucosal vaccine: Nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 170:495-502.
248. Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Gluck R. 2004. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine. Vaccine 22:4390-4396.
249. Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Felix N, White GL, Lowell GH, Burt DS. 2001. Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine 20:218-225.